Heparins, heparinoids and hirudin derivatives. Prophylaxis and therapy of venous thromboembolism;Heparine, heparinoide und hirudin-derivate: Prophylaxe und therapie venoser thromboembolien

Krankenhauspharmazie

Volumn 20, Issue 8, 1999, Pages 317-332

  Lipp, Hans Peter ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Heparin; Heparinoids; Low molecular weight heparin; Prophylaxis; Therapy; Venous thromboembolism

Indexed keywords

HEPARIN; HEPARINOID; HIRUDIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN;

HOME CARE; HUMAN; MOBILIZATION; RECURRENT DISEASE; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0032783134     PISSN: 01737597     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (140)

1. Agnelli G, Piovella F, Buoncristian P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998;339:80-5.
2. Andrassy K, Eschenfelder V. Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb Res 1996;81(Suppl 2): S29-S38.
3. Bauersachs RM, Lindhoff-Last E, Wolff U, Ehrly AM. Aktuelles Management der tiefen Venenthrombose. Med Welt 1998;49:194-214.
4. Beijering RJR, ten Cate H, ten Cate JW. Clinical applications of new antithrombotic agents. Ann Hematol 1996;72:177-83.
5. Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb Haemost 1996;76:529-34.
6. Bergqvist D, Benoni G, Björgell O, et al. Low-molecular-weight heparin (Enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696-700.
7. Bergqvist D, Burmark US, Flordal PA, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995;82:496-501.
8. Blättler W, Partsch H, Hertel T. Leitlinien zur Diagnostik und Therapie der tiefen Bein-/ Beckenvenenthrombose. Phlebologie 1996; 25:199-203.
9. Bornkessel B. Danaparoid bei Heparin-induzierter Thrombozytopenie Typ II. Krankenhauspharmazie 1997;18:239-41.
10. Bounameuax H, Huber O, Khabiri E, et al. Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight-heparin. Arch Surg 1993;128:326-8.
11. Breddin HK. Heparinoids. Hämostaseologie 1997;17:49-53.
12. Breddin HK. Neue Aspekte zu Hirudin. Med Welt 1997;48:64-6.
13. Brieger D, Dawes J. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb Haemost 1997;77:317-22.
14. Charbonnier BA, Fiessinger JN, Banga JD, et al. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. Thromb Haemost 1998;79:897-901.
15. Charland SL, Klinter DEJ. Low-molecular-weight heparins in the treatment of pulmonary embolism. Ann Pharmacother 1998;32: 258-63.
16. Chesterman CN, Chong BH. Uses of heparin. BMJ 1993;306:871-2.
17. Clagett GP, Anderson FA, Geerts W, et al. Prevention of venous thromboembolism. Chest 1998;114(Suppl):531-60.
18. Cohen M, Demers C, Gurfinkel E, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337:447-52.
19. Colwell CW, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J Bone Joint Surg 1994;76-A:3-14.
20. Conrad KA. Clinical pharmacology and drug safety: lessons from hirudin. Clin Pharmacol Ther 1995;58:123-6.
21. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged Thromboprophylaxis following hip replacement surgery - results of a double-blind, prospective, randomized, plazebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997;77:26-31.
22. Dechavanne M, Ville D, Berruyer M, et al. Randomized trial of a low molecular weight heparin (Kabi 2165) versus adjusted dose subcutaneous standard heparin in the prophylaxis of deep venous thrombosis after elective hip surgery. Haemostasis 1989;1:5-12.
23. de Groot MR, Büller HR, ten Cate JW, van Marwjik Kooy M. Use of a heparin nomogram for treatment of patients with venous thromboembolism in a community hospital. Thromb Haemost 1998;80:70-3.
24. Diehm C, Stammler F, Amendt K. Die tiefe Venenthrombose: Diagnostik und Therapie. Dtsch Ärztebl 1997;94:A301-11; B253-63; C235-45.
25. Eriksson BI, Kälebo P, Ekman S, et al. Direct thrombin inhibition with rec-Hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 1994;72:227-31.
26. Eriksson BI, Ekman S, Kälebo P, et al. Prevention of deep vein thrombosis after total hip replacement. Direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996;347:635-9.
27. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337:1329-35.
28. Etminan M, Wright JM, Carleton BC. Evidence-based pharmacotherapy: review of basic concepts and applications in clinical practice. Ann Pharmacother 1998;32:1193-200.
29. Fareed J, Walenga JM, Hoppensteadt D, et al. Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization. Semin Thromb Haemost 1989;15:440-59.
30. Fiessinger JN, Lopez-Fernandez M, Gatterer E, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996;76:195-9.
31. Fobbe F, Koppenhagen K. Diagnostik der symptomatischen und asymptomatischen venösen Thrombose. Hämostaseologie 1995; 43:148-55.
32. Fricker JP, Vergnes Y, Schach R, et al. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest 1988;18:561-7.
33. FRISC study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
34. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996;335:1816-28.
35. Goldhaber SZ. Pulmonary Embolism. N Engl J Med 1998;339:93-104.
36. Green D, Hirsh J, Heit J, et al. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994;46:89-109.
37. Greinacher A, Alban S. Heparinoide als eine Alternative für die parenterale Antikoagulation bei Patienten mit Heparin-induzierter Thrombozytopenie. Hämostaseologie 1996; 16:41-9.
38. Greinacher A. Heparin-induzierte Thrombozytopenien. Internist 1996;37:1172-8.
39. Gupta AK, Kovacs MJ, Sauder DN. Heparininduced thrombocytopenia. Ann Pharmacother 1998;32:55-9.
40. Haas S. Prävention, Diagnostik und Therapie von Thrombosen in der Orthopädie und Unfallchirurgie. Orthopäde 1997;26:1062-74.
41. Haas S. Management of venous thromboembolism - current status and future perspectives. Hämostaseologie 1998;18:18-26.
42. Haas S. Die Zeit nach der Europäischen Konsenus-Erklärung. Hämostaseologie 1995;26: 132-7.
43. Haentjens, and the Belgian Fraxiparine Study Group. Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium). Injury 1996;27: 385-90.
44. Haines ST, Bussey HI. Diagnosis of deep vein thrombosis. Am J Health Syst Pharm 1997;54:66-74.
45. Haines ST, Bussey HI. Thrombosis and the pharmacology of antithrombotic agents. Ann Pharmacother 1995;29:892-905.
46. Harder S, Thürmann P. Clinically important drug interactions with anticoagulants. Clin Pharmacokinet 1996;30:416-44.
47. Harenberg J, Schmitz-Huebner U. Therapie der Beinvenenthrombose mit niedermolekularen Heparinen. Dtsch Ärztebl 1997;94: 2257-60.
48. Harenberg J, Huhle G, Piazolo L, Heene DL. Klinischer Einsatz von Heparinoiden. Hämostaseologie 1996;16:50-5.
49. Harenberg J, Wuester B, Pfitzer M, et al. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Haemost 1993;19 (Suppl 1):116-21.
50. Hawkins DW, Langley PC, Krueger KP. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. Am J Health Syst Pharm 1997;54:1185-90.
51. Hirsh J. Is the dose of warfarin prescribed by American physicians unnecessarily high? Arch Intern Med 1987;147:769-71.
52. Hirsh J. Heparin. N Engl J Med 1991;24: 1565-71.
53. Hirsh J. Oral Anticoagulant Drugs. N Engl J Med 1991;324:1865-75.
54. Hirsh J, Crowther M. Low molecular weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results. Thromb Haemost 1997;78:689-92.
55. Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 1992;102(Suppl):312S-25S.
56. Howard AW, Aaron SD. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. Thromb Haemost 1998;79:902-6.
57. Howard PA. Dalteparin: a low molecular weight heparin. Ann Pharmacother 1997;31: 192-203.
58. Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. Arch Surg 1992;127: 310-3.
59. Hull RD, Feldstein W, Stein PD, Pinco GF. Cost-effectiveness of pulmonary embolism diagnosis. Arch Intern Med 1996;156:68-72.
60. Hull RD, Pineo GF, Valentine KA. Treatment and prevention of venous thromboembolism. Semin Thromb Haemost 1998;24(Suppl 1): 21-31.
61. Hull RD, Raskob GE, Rosenbloom D, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. Arch Intern Med 1997;157:289-94.
62. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
63. Janssen MCH, Verbruggen H, Wollersheim H, et al. D-dimer determination to asses regression of deep venous thrombosis. Thromb Haemost 1997;78:799-802.
64. Kakkar VV. Niedermolekulare Heparine und Reviparin-Natrium. Arzneimitteltherapie 1993;11(Suppl 15):7-8.
65. Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993;341:259-65.
66. Kakkar VV. Dalteparin prevention of recurrent deep vein thrombosis: a study versus warfarin. Haemostasis 1994;24(Suppl 1):S45.
67. Kirchmaier CM, Wolf H, Schäfer H, Ehlers B, et al. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Int Angiol 1998;17: 135-45.
68. Kleine P, Lühmann U, Wagner HH, Freise J, et al. Akute Lungenembolie. Klinik, Pathophysiologie, Diagnostik und Therapie. In: Feiereis H, Hrsg. Beiträge zur Diagnostik pulmonaler Erkrankungen. München: Hans Marseille Verlag GmbH, 1988.
69. Koopman MMW, Prandoni P, Piovella F. et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7.
70. Lefevre G, Duval M, Gauron S, et al. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clin Pharmacol Ther 1997;62:50-9.
71. Leizorovicz A. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis - an updated meta-analysis. Drugs 1996;52(Suppl 7):30-7.
72. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. Arch Intern Med 1995;155:601-7.
73. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
74. Levine MN, Gent M, Hirsh J, et al. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. Arch Intern Med 1996;156:851-6.
75. Leyvraz PF, Richard J, Bachmann F, et al. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 1983;309:954-8.
76. Leyvraz RF, Bachmann F, Hock J, et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ 1991;303:543-8.
77. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994;309:299-04.
78. Leizorovicz A, Picolet H, Peyrieux JC, et al. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. Br J Surg 1991; 78:412-6.
79. Lipp HP. Heparine, Heparinoide und Hirudoide bei Lungenembolie und Thrombosen. Pharm Ztg 1997;142:11-8.
80. Lipp HP. Sichere Handhabung von Gerinnungshemmern: Vitamin-K-Antagonisten im Vergleich. Pharm Ztg Prisma 1998;5:99-107.
81. Lipp HP. Heparin-induzierte Thrombozytopenie Typ II - Stellenwert von Lepirudin. Krankenhauspharmazie 1997;18:584-8.
82. Litin SC, Gastineau DA. Current concepts in anticoagulant therapy. Mayo Clin Proc 1996; 70:266-72.
83. Litin SC, Heit JA, Meers KA. Use of low-molecular-weight heparin in the treatment of venous thromboembolic disease: answers to frequently asked questions. Mayo Clin Proc 1998;73:545-51.
84. Lowe GDO, Greer IA, Cooke TG, et al. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992;305:567-74.
85. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993;70:554-61.
86. Malsch R, Harenberg J. Eigenschaft und Analytik von Heparinoiden. Hämostaseologie 1996;16:1-5.
87. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74:1-23.
88. Martineau P, Tawil N. Low-molecular-weight heparins in the treatment of deep-vein thrombosis. Ann Pharmacother 1998;32:588-98.
89. Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindication to coumarin. Thromb Haemost 1994;71:7-11.
90. Nemeth JS, Marxen TL, Piltz GW. Weight-based protocol for improving heparin therapy. Am J Health Syst Pharm 1996;53: 1164-6.
91. Noble S, Peters DH, Goa KL. Enoxaparin: a reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs 1995;49: 388-410.
92. Noble S, Spencer CM. Enoxaparin: a review of its clinical potential in the management of coronary artery disease. Drugs 1998;56:259-72.
93. Partsch H, Blättler W. Leitlinien zur Thromboembolieprophylaxe. Phlebologie 1996;25: 261-6.
94. Partsch H, Köhn H, Mostbeck A. Verändertes Behandlungskonzept bei der tiefen Beinvenenthrombose. Münch Med Wochenschr 1999;141:28-32.
95. Piazolo L, Maisch R, Harenberg J, Heene DL. Pharmakodynamik von chemisch modifizierten niedermolekularen Heparinen. Hämostaseologie 1996;16:35-40.
96. Pineo GF, Hull RD. Prevention and treatment of venous thromboembolism. Drugs 1996; 52:71-92.
97. Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994;72:191-7.
98. Planes A, Vochelle N, Fagola M, et al. Prevention of deep vein thrombosis after total hip replacement: the effect of low-molecular-weight heparin with spinal and general anesthesia. J Bone Joint Surg Br 1991;73-B:418-23.
99. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125:1-7.
100. Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost 1997; 78:141-4.
101. Rader CP, Kramer C, König A, et al. Vergleich zwischen niedermolekularen und unfraktionierten Heparinen (PTT gesteuert) in der Thromboseprophylaxe bei Patienten mit totalendoprothetischem Ersatz von Hüft-und Kniegelenk. Z Orthop 1997;135:52-7.
102. Raj G, Kumar R, McKinney P. Long-term oral anticoagulant therapy: update on indications, therapeutic ranges and monitoring. Am J Med 1994;307:128-32.
103. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial Ann Intern Med 1993;119:874-81.
104. Raschke RA, Gollihare B, Peirce JC. The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Arch Intern Med 1996;156:1645-9.
105. Samana MM, Bara L, Gouin-Thibault J. New data on the pharmacology of heparin and low molecular weight heparins. Drugs 1996;52 (Suppl 7):8-15.
106. Schafer AI. Antiplatelet therapy. Am J Med 1996;101:199-209.
107. Schiele F, Vuillemenot A, Kramarz P, et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Haematol 1995;50: 20-5.
108. Schlicht JR, Sunyecz L, Weber RJ, et al. Reevaluation of a weight-based heparin-dosing nomogram: is institution-specific modification necessary? Ann Pharmacother 1997;31: 1454-9.
109. Schrader J, Haas S. Unfraktioniertes Standardheparin versus niedermolekulare Heparine. Internist 1993;34:1053-8.
110. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337: 663-9.
111. Siragusa S, Cosmi B, Piovella F, Hirsh J, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a metaanalysis. Am J Med 1996;100:269-77.
112. Skoutakis VA. Danaparoid in the prevention of thromboembolic complications. Ann Pharmacother 1997;31:876-87.
113. Spinier SA, Nawarskas JJ. Low-molecular-weight heparins for acute coronary syndromes. Ann Pharmacother 1998;32:103-10.
114. Stammler F, Diehm C. Niedermolekulare Heparine bei venöser Thromboembolie. Dtsch Med Wochenschr 1998;123:604-11.
115. Stöckli TC, Walther A, Görres G, et al. Heparin-induzierte Thrombopenie und Thrombose. Schweiz Med Wochenschr 1996;126: 483-8.
116. Thomas DP. Does low molecular weight cause less bleeding? Thromb Haemost 1997; 78:1422-5.
117. 116.THRIFT Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992;305:567-74.
118. Torholm C, Broeng L, Jorgensen PS, et al. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery: a plazebo-controlled study. J Bone Joint Surg Br 1991;73-B:434-8.
119. Trujiilo TC, Nolan PE. Unfractionated heparin in acute coronary syndromes: has its time come and gone? Am J Health Syst Pharm 1998;55:2402-9.
120. Valles JA, Vallano A, Torres F, et al. Multi-centre hospital drug utilization on the prophylaxis of venous thrombembolism. Br J Clin Pharmacol 1994;37:255-9.
121. Vanholder R, Camez A, Veys N, et al. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost 1997;77:650-5.
122. Velten U, Mücke T. Heparin-induzierte Thrombozytopenie. Anästhesiol Intensivmed 1996;2:76-80.
123. Verstraete M. Prophylaxis of venous thromboembolism. BMJ 1997;314:123-5.
124. Walsh-McMonagle D, Green D. Low-molecular-weight heparin in the management of trousseau's syndrome. Cancer 1997;80:649-55.
125. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998;79:1-7.
126. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-5.
127. Wells PS, Holbrook AM, Crowther R, Hirsh J. Interactions of Warfarin with drugs and food. Ann Intern Med 1994;121:676-83.
128. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98.
129. Wenzel E, Wenzel U, Heinrich W, et al. Thromboembolieprophylaxe im Bereich so genannter "noch nicht zugelassener Indikationsgebiete". Hämostaseologie 1995;15: 160-6.
130. Wolf H, Encke A, Haas S, Welzel D. Comparison of the efficacy and safety of Sandoz low-molecular weight heparin and unfractionated heparin: Interim analysis of a multicenter trial. Semin Thromb Haemost 1991;17:343-6.
131. Horbach T, Wolf H, Michaelis HC, et al. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement. Thromb Haemost 1996;75:246-50.
132. Planes A, Vochelle N, Fagola M, et al. Comparison of two low-molecular weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Blood Coagul Fibrinolysis 1998;9: 499-505.
133. Planes A, Samama NM, Lensing AWA, et al. Prevention of deep vein thrombosis after hip replacement - comparison between two low molecular weight heparins, tinzaparin and enoxaparin. Thromb Haemost 1999;81:22-5.
134. Adolf J, Fritsche M, Haas, et al. Comparison of 3000 IU aXa of the low molecular weight heparin Certoparin with 5000 IU aXa in prevention of deep vein thrombosis after total hip replacement. Int J Angiol 1999;18:122-6.
135. Pauschert R, Diehm C, Stammler F. Leitlinien zur Thromboseprophylaxe in der Orthopädie. Z Orthop 1998;136:471-9.
136. Sanson B-J, Lensing AWA, Prins MH, et al. Safety of low-molecular weight heparin in pregnancy: a systematic review. Thromb Haemost 1999;81:668-72.
137. Girolami B, Bernardi E, Prins MH, et al. Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysis. Thromb Haemost 1999;81: 715-22.
138. Eriksson H, Eriksson UG, Frison L, et al. Pharmacokinetics and pharmacodynamics of Melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999;81:358-63.
139. Lopaciuk S, Bielska-Falda, H, Noszcyk W, Bielawiec M, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999;81:26-31.
140. Hull RD, Brant RF, Pineo GF, Stein PD, et al. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med 1999;159:137-41.